Inflazione USA a giugno +0,3% m/m e +2,7% a/a, in linea con le attese. Futures contrastati, Fed più cauta su eventuali tagli dei tassi.
Alternus Clean Energy is a forward-thinking utility-scale clean energy independent power producer that effectively leverages transatlantic markets to amplify its impact and create value for shareholders. With a strategic focus on solar, battery storage and microgrids, Alternus has a robust portfolio and pipeline featuring operational and projects in development across America and Europe, backed by long-term power purchase agreements that ensure stable revenue streams.
Founded in 2015, Perfect Corp. is a beautiful AI Company and global leader in enterprise SaaS solutions. As an innovative powerhouse in using artificial intelligence (AI) to transform the beauty and fashion industries, Perfect empowers major beauty, skincare, fashion, jewelry brands and retailers by providing consumers with omnichannel shopping experiences through augmented reality (AR) product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables personalized, enjoyable, and engaging shopping journey.
In addition, Perfect also operates a family of YouCam consumer apps for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. With the help of technologies, Perfect helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com
Founded in 2010, AgEagle was originally formed to pioneer proprietary, professional-grade, fixed-winged drones and aerial imagery-based data collection and analytics solutions for the agriculture industry. Today, the Company is earning distinction as a globally respected market leader offering customer-centric, advanced, autonomous unmanned aerial systems ("UAS”) which drive revenue at the intersection of flight hardware, sensors and software for industries that include agriculture, military/defense, public safety, surveying/mapping and utilities/engineering, among others. AgEagle has also achieved numerous regulatory firsts, including earning governmental approvals for its commercial and tactical drones to fly Beyond Visual Line of Sight ("BVLOS”)and/or Operations Over People ("OOP”) in the United States, Canada, Braziland the European Union and being awarded Blue UAS certification from the Defense Innovation Unit of the U.S. Department of Defense.
BREAKTHROUGH ARTIFICIAL INTELLIGENCE. Our proprietary AI-technology will transform education by delivering dynamic, real-time and two-way human-like conversations with our AI-Super Teachers.
AI-POWERED SUPER TEACHERS: Imagine having a teacher available 24/7 who adapts to your learning style and offers instant feedback. Our AI-powered teachers make this into reality. Our algorithms and natural language processing provide personalized lessons, conversations, and offer real-time feedback to enrich your learning experience.
COMBINING PROFESSIONAL AND LANGUAGE SKILLS LEARNING; Professional skills and topics covered include hospitality, nursing, engineering, AI coding, computer science, social media marketing, high school exam prep, and much more.
CUSTOMIZED LEARNING PATHS AI algorithms analyze a learner's proficiency, learning style, strengths, weaknesses, and goals to create a tailor-made learning path. This ensures that the content is relevant to the individual.
A UNIQUE AI-POWERED EVALUATION SYSTEM This simulates real-life scenarios to provide the most meaningful performance assessment and proof of ability.
FROM A FINANCIAL PERSPECTIVE, THE POTENTIAL IS ENORMOUS Our platform meets specific training needs for career development across multiple industries, ensuring lucrative engagement and robust ROI. Sectors like coding and hospitality alone present giant market opportunities.
ALPHA COGNITION, INC is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative disease, such as Alzheimer’s disease and Cognitive Impairment with mild Tramautic Brain Injury (“mTBI”). The Company’s first product ZUNVEYL is approved by the U.S. Food and Drug Administration (FDA) as a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.
Launched in 2018, ALT5 Sigma Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma Inc., through its subsidiaries, offers two main platforms to its customers: "
ALT5 Pay" and "ALT5 Prime". ALT5 Sigma Inc. processed over US$1.2 billion in cryptocurrency transactions in 2023. ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
CEL-SCI Corporation (NYSE American: CVM) is a biotechnology company that believes that boosting a cancer patient’s immune system before surgery, radiotherapy and chemotherapy, while it is still intact, should provide the greatest possible impact on survival.
Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules.
Focus Universal Inc. (NASDAQ:FCUV) is a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G. The company has developed five disruptive patented technology platforms with 28 patents and patents pending in various phases and 8 trademarks pending in various phases to solve the major problems facing hardware and software design and production within the industry today. These technologies combined to have the potential to reduce costs, product development timelines and energy usage while increasing range, speed, efficiency, and security. Focus currently trades on the Nasdaq Markets.
Greenland Technologies Holding Corp (NASDAQ: GTEC) is a leading developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling vehicles.
Impact Biomedical Inc.(IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.
By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add to our portfolio.
Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty payments.
Lipella Pharmaceuticals (Nasdaq: LIPO) is a Pittsburgh-based clinical-stage biotechnology company focused on developing treatments for serious diseases with significant unmet needs. The company has a broad portfolio of three promising IND-approved assets and operates an in-house manufacturing facility. Lipella’s proprietary drug delivery platform utilizes liposomal formulations of tacrolimus, enabling localized treatment with minimal systemic exposure. The company is advancing two lead assets in Phase 2 clinical trials: LP-10, targeting hemorrhagic cystitis, and LP-310, an oral rinse for Oral Lichen Planus. Both programs leverage the 505(b)(2) regulatory pathway to expedite development and reduce costs. With pivotal clinical milestones expected over the next 18 months, Lipella is well-positioned for potential partnerships and licensing agreements.
NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
About PetVivo Inc: PetVivo Inc. is based in Minneapolis, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize medical devices and therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to internally develop and/or in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
We have two areas of focus:
1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, Behçet’s disease, and pediatric Crohn’s disease.
2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure and viral disease including Ebola, Marburg and COVID-19.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Lucosky Brookman is a corporate law firm with offices in New York, New Jersey, Philadelphia, Kansas City, Washington D.C. and Texas, representing both domestic and international clients in sophisticated corporate and securities transactions, mergers and acquisitions, secured and unsecured lending transactions, PIPEs, commercial and securities litigation, intellectual property, insurance coverage and defense, real estate and general corporate matters.
The Firm was established out of a desire to dedicate more time and effort to directly serve a select clientele in the small and middle markets. At Lucosky Brookman, we see the world through our clients' eyes. It is our mission to provide clients with exceptional legal representation and hands-on attention. We are able to do this by listening to our clients and anticipating their needs.
Our offices are located in New York, NY, Woodbridge, NJ, Pennsylvania, PA, Austin, TX, Washington D.C. and Kansas City.
Money Channel NYC is a media consulting firm specializing in strategic media relations, C-suite advisory, and brand amplification for over 20 years. Located in New York City’s Financial District, they provide tailored media solutions to help clients build lasting visibility. Their Moneyball Networks division organizes large-scale networking events, connecting clients with industry leaders and influencers while offering additional support in fostering strategic partnerships to expand business opportunities.
The Nuvo Group provides financial printing, digital publishing and EDGAR SEC electronic filing services to some of the world’s most respected financial institutions. The Corporation possesses the tools, team and advanced technologies to ensure an exceptional customer experience - ease of process, rapid execution, regulatory compliance and uncompromising accuracy. Our Mission & Vision is to consistently perform in ways that make our customers’ jobs easier, and their printing and filing faster, to leverage the most experienced talent, effective tools and advanced technologies in order to simplify, accelerate and enhance the end product we proudly deliver to our customers — on time, in format and on budget.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company's story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant investors to each company. The digital marketing strategy is combined with virtual and in-person conferences to increase the level of engagement between investors and companies. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com.
Calabrese Consulting LLC has decades of experience and a vast network of professionals, bringing a unique approach to successfully navigate each business challenge.
With expertise in audit readiness and advisory, due diligence, financial reporting, initial public offerings, SPAC transactions, Sarbanes-Oxley compliance, outsource accounting, and outsourced CFO/controller services, we provide you with a tailored service approach to meet the ever-evolving needs of your organization. Whether your company is an emerging public or private company, or whether your organization just needs some additional support to get through a deadline, our team of experts can guide you through each and every stage of your business journey.
Harter Secrest & Emery is a full-service law firm founded in 1894, with offices in Rochester, Buffalo, Albany, Corning, and New York City. With over 125 lawyers, we offer the depth and breadth of legal talent and experience necessary to achieve exceptional results for our local, regional, and national clients.
Our Securities and Capital Markets attorneys have been honored by Chambers USA: America’s Leading Lawyers for Business for several years. Chambers USA, the worldwide leader in attorney and firm rankings, has been ranking the best lawyers since 1990, and now covers over 185 jurisdictions. The Chambers USA 2020 edition highlighted our “impressive portfolio of public and private clients, including private equity funds, venture capital players and startups as well as companies in the telecommunications, pharmaceuticals and manufacturing sectors.”
Pryor Cashman is an award-winning midsize full service law firm headquartered in New York City. With over 200 attorneys, our firm spans across three offices, including locations in both Miami and Los Angeles — but we serve a diverse client base that spans around the globe. No matter the office or location, we are known for getting the job done right, and doing it with integrity, efficiency, and style.
Share Media offers a specialized service designed for partners of private companies or CEO’s of publicly traded companies. We provide personalized LinkedIn content, articles, graphics, targeted organic outreach services aimed at cultivating connections, enhancing branding, increasing exposure, and positioning the CEO and company as a respected leader in their industry. Our goal is to deliver tangible results, on a month to month basis, helping CEO’s achieve their business goals or capital markets objectives with defined and measurable outcomes.
NewMediaWire distributes press releases on behalf of hundreds of publicly traded companies, as well as private corporations, non-profits and other public sector organizations. Founded and staffed by industry veterans, we offer a full complement of services including specialized delivery to financial sites and posting of photos and multimedia content. In addition, NewMediawire offers international and specialized services such as IR websites and industry specific distribution.
Zacks Small-Cap Research prepares independent company-sponsored research and related content for distribution through a multitude of investor and media channels, both traditional and social, delivering broad awareness worldwide among serious, long-term investors. We create deep understanding of the company, hopefully generating significant interest in investment, through the quality of our analysts, the depth of their research and the breadth of our distribution.
New to The Street Elevates SPARTAN Conference with Exclusive Media Coverage
New to The Street, the premier TV brand, will be live at the Spartan Conference, conducting exclusive interviews with participating companies and sponsors. With its three 7-story Reuters billboards in NYC and a 1.7 million+ YouTube audience, New to The Street guarantees unmatched visibility. Brands will also receive special consideration for Bloomberg TV and Fox Business broadcasts nationwide as sponsored content, further amplifying exposure.
Industries of the Americas is a manufacturing plant that was built in 1988 with the help of J&J to make latex products for the American worker and healthcare professionals. Located in Alabama, it has millions of latex gloves that is fentanyl proof to protect law enforcement and for protection of the American worker in the workplace. With the President Trump's manufacturing initiative, our company plans to become fully operational with private and government contracts for our green latex gloves. We also will produce thermal hot and cold packs for American consumers and healthcare workers. Our business strategy is called "The Rural Advantage" as we plan on opening a closed Rural factories that can employ thousands of American workers, making American products for the American worker and consumer.
Inspire is an owner of general practice veterinary clinics in the United States. Inspire acquires practices, and, in many cases real estate, and then works with teams on a long-term basis to improve and maintain hospital operations, grow revenues and maximize earnings.
Traditional veterinary hospitals, both privately and corporately owned, have run on a top-down model. Ours is bottom up. Welcome to the first employee-owned veterinary group. The only thing it changes is everything.
Lafayette Energy Corp (“LEC”) is a Utah based Oil and Gas exploration company focused on developing its large core project in the Asphalt Ridge of the Uintah Basin, Utah.
With unprecedented rates of medical innovation, many life science companies and academic institutions are struggling to bring their products to market fast enough to realize their value.
NAYA Biosciences aims to address this challenge through an agile and synergistic platform, backed by access to capital and public markets & driven by experienced, entrepreneurial leadership.
Our unique business model is based on a portfolio approach, optimizing the risk-return investment profile through steady, scalable, profitable revenues augmented by the partnering upside of disruptive clinical-stage therapeutics.
Fueled by this value creation approach, we aim to continue our strategic acquisition of undervalued specialty assets, accelerate their clinical development and commercialization, and capitalize on their potential to transform patients’ lives.
Company Overview & Strategy Sono-Tek Corporation (Nasdaq: SOTK) is a global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts in diverse industries including medical devices, semiconductors, microelectronics, alternative energy, advanced industrial manufacturing, and research and development sectors. Sono-Tek has a long history of providing advanced coating solutions to the medical device industry, enabling precision coatings for life-saving technologies such as stents, balloons, diagnostic devices, and various drug delivery platforms. At the same time, our expertise in semiconductor and microelectronics applications continues to expand, as customers increasingly turn to Sono-Tek for solutions supporting next-generation chips, displays, and sensors. Alongside these markets, our technologies are also leading the way in next-generation clean energy coatings for fuel cells, carbon capture, advanced solar cells, and various other advanced industrial applications, underscoring the versatility and broad reach of Sono-Tek’s ultrasonic coating platforms. Our product line is rapidly evolving, transitioning from R&D tools to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Our comprehensive suite of thin film coating solutions and application consulting services ensures unparalleled results for our clients and helps some of the world’s most promising companies achieve technological breakthroughs and bring them to market. The company strategically delivers its products to customers through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse sectors around the globe. Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop microscopic coating technologies that enable better outcomes for our customers’ products and processes.
NeuroSense Therapeutics, Ltd. (Nasdaq:NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
AmpliTech designs, develops, and manufactures custom leading-edge RF components for the Commercial, SATCOM, Space, and Military markets. These designs cover frequencies from 50 kHz to 44 GHz. AmpliTech also has developed new products for the 5G/6G wireless ecosystem and infrastructure with unparalleled performance. In addition to this rapidly emerging market, AMPG has also developed solutions for Quantum Computing, with cutting edge technology. We continue to blaze trails in our commitment to enable and accelerate the arrival of true 5G/6G architecture and contribute to the U.S. being the leader and first to reach the coveted position of Quantum Supremacy.
Sichenzia Ross Ference Carmel LLP provides experienced, professional representation in all matters involving the securities industry, as well as in general corporate, litigation, real estate and trusts & estates matters.
Our clients range from start-ups to established, listed companies. They include public and private corporations, partnerships, broker-dealers, investment banks, investment advisors, registered personnel, public and corporate customers and investors, and other entities. We also advise institutional investors on transactions involving complex securities laws. Our practice includes the representation of clients located in the United States and throughout the world.
Our areas of expertise include corporate finance, including initial and secondary public offerings, corporate and commercial transactions, mergers and acquisitions, securities litigation and arbitration, administrative practice before regulatory agencies, and broker-dealer regulation. In addition, we are experts at listing companies on both the NASDAQ and New York Stock Exchange and provide guidance to Boards of Directors and corporate managers who now operate in an increasingly complex and changing landscape of securities rules, litigation risks, regulatory oversight and investor scrutiny.
Our estate planning lawyers advise individuals and families on estate planning (wills and trusts) and estate administration (probate and intestacy). They also work in the probate courts to assist clients with a smooth estate administration, advising executors/administrators.
The MUSQ Global Music Industry ETF (NYSE: MUSQ) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of MUSQ Global Music Industry Index (MUSQIX). The index aims to provide focused exposure to the entire music ecosystem and track companies with a core business interest in the global music industry.
Skyline Corporate Communications Group, LLC, with offices in New York City and Boston, is an investor relations and corporate communications firm that provides strategic messaging and investor communications consulting services for pre-IPO and publicly traded corporations. Skyline delivers strategic assistance for companies in the financial markets and investment community by helping them effectively communicate their corporate message and competitive advantages while assisting its clients to build their investor relations efforts into industry leading platforms.
Using strategic counsel customized to each company’s unique needs, Skyline’s team has collectively worked with hundreds of U.S.-listed public companies worldwide across diverse industries and various market caps. Skyline Corporate Communications Group, LLC has experience with shareholder activism and crisis communications, and also works with late-stage private companies to help prepare them to enter the public marketplace.
For further information, please visit Skyline Corporate Communications Group, LLC’s website at www.skylineccg.com.
PAG provides a comprehensive range of aerospace services, including precision machining across diverse airframes, advanced non-destructive testing, and specialized contracts spanning aerospace and government sectors. With a continuous focus on expanding our capabilities and offerings, our dedication to excellence remains steadfast. Explore our expertise in precision machining, advanced NDT testing, and specialized aerospace and government contracting services tailored to your needs.
MaNaDr Pte Ltd, a pioneer in the application of technology in the healthcare field, with 100% capital from Singapore, making connecting patients and doctors easier with special features, including Appointment Booking, TeleConsultation, TeleLab, MaNaCare, MaNaShop, etc.
We care for your health as you do. MaNaDr services can also be extended to your family members, allowing your loved ones to easily connect with reputable doctors quickly.
Siyata Mobile (SYTA) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Siyata Mobile is traded on The NASDAQ Capital Market under the symbol “SYTA.”
At Bush & Associates, we pride ourselves on delivering high-quality, client-focused services that foster trust and confidence with stakeholders and investors alike. Bush & Associates CPAs is a leading external audit firm that specializes in auditing public companies and those preparing to go public. We’re not just auditors—we’re partners in your journey to financial transparency and growth. Our deep expertise in capital markets, coupled with a client-focused approach, ensures that your company is audit-ready and compliant with regulatory requirements. Whether you’re navigating your first public filing or scaling further, our team is here to support you every step of the way. We invite you to stop by and discuss how our tailored audit services can help position your business for success in today’s competitive market. Let’s connect and explore how we can partner on your path to growth!
Astiva Health is a Medicare Advantage Prescription Drug (MAPD) health plan committed to redefining the standards of personalized and comprehensive healthcare. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members. The organization prioritizes a culturally responsive approach to healthcare, offering multilingual solutions for customer service, marketing materials, and educational resources. Astiva Health’s dedication to serving the underserved population is not only fulfilling a critical societal need but also positioning the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves.
WiSA Technologies, Inc. (NASDAQ: WISA), formerly known as Summit Wireless Technologies, Inc., is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung; LG; Klipsch; Bang & Olufsen; Xbox, a subsidiary of Microsoft; and others, the company delivers immersive wireless sound experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. WiSA Technologies, Inc. is a founding member of WiSA™ (the Wireless Speaker and Audio Association) and works in joint partnership to champion the most reliable interoperability standards across the industry. The company is headquartered in Beaverton, Oregon with sales teams in Taiwan, China, Japan, and Korea.
Guident commercializes patented technology to enable safer Autonomous Vehicles (AV) and devices by providing industry-leading AV remote monitor, control, assistance, and passenger support services. To learn more, please visit www.guident.com.
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer. With the addition of OST-TDC, considered a next generation Antibody Drug Conjugate (ADC) platform technology, we will be targeting Ovarian, Lung and Pancreatic cancer.
Our goal is to identify lead candidates in the treatment of Osteosarcoma and other solid tumors for clinical development, regulatory approval and commercialization. Starting with the most common genetic mutation found in Osteosarcoma, OS Therapies has identified a lead candidate in HER-2 Osteosarcoma with a goal of rapid clinical and regulatory analysis and review. This will be immediately followed in parallel with the OST-TDC development.
Elegran | Forbes Global Properties is a leading NYC real estate brokerage and the exclusive Forbes Global Properties partner for New York. It provides ultra-high-net-worth individuals and institutions with global access to luxury real estate as an alternative investment opportunity. Known for its innovative, client-first approach, Elegran specializes in high-end residential sales, new developments, and luxury rentals, offering exclusive access to premier NYC properties.
Elegran Capital & Advisory sources and co-invests in prime real estate across office, industrial, retail, and multi-family sectors, delivering high-value investment opportunities to select clients.
Together Elegran strives to humanize real estate by delivering a seamless, white-glove experience in NYC and top global real estate markets.
Western Alaska Minerals (WAM) is a mineral exploration company operating in the Illinois Creek Mining District in western Alaska. Headquartered in both Alaska and Arizona, WAM brings together a team of seasoned professionals with a shared vision of pioneering new frontiers in mineral exploration. With over 100 years of combined Alaskan exploration success, the principals of the company have participated in major discoveries such as Donlin Gold(39 million oz), Bornite Copper(now South 32/Trilogy JV) and Greens Creek Mine, the largest US silver producer operated by Hecla Mining.
Western Alaska Minerals controls the entire Illinois Creek Mining District with 100% ownership of 73,000 acres of State of Alaska mining claims with no underlying royalties. Our value is underpinned by two resources, the extremely high grade Waterpump Creek deposit with 75 million Aq Eq oz grading 980 g/t silver equivalent and the past producing Illinois Creek gold deposit that contains 525,000 Au Eq oz of combined indicated and inferred resources.
Now that the markets have recognized the upside potential of gold and silver, WAM provides an opportunity to invest in high grade silver and gold deposits in a safe jurisdiction with significant potential.
As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.
OS Therapies (NYSE-A: OSTX) is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Money Channel NYC is a media consulting firm specializing in strategic media relations, C-suite advisory, and brand amplification for over 20 years. Located in New York City’s Financial District, they provide tailored media solutions to help clients build lasting visibility. Their Moneyball Networks division organizes large-scale networking events, connecting clients with industry leaders and influencers while offering additional support in fostering strategic partnerships to expand business opportunities.
As a PCAOB-registered firm and the 52nd largest accounting firm in the nation, Grassi delivers high-quality audits with precision and expertise for public companies and those preparing for an IPO. Our SEC & Capital Markets team provides hands-on guidance through IPOs, follow-on offerings, and equity and debt financing transactions. We tailor post-audit recommendations to your industry, ensuring ongoing compliance and strategic growth.
The Nuvo Group is a leading provider of financial printing, SEC filing, and corporate communication services, offering tailored solutions for public companies, investment banks, and law firms. With expertise in SEC EDGAR filings, proxy design and production, iXBRL tagging, and virtual data rooms, The Nuvo Group ensures seamless compliance and accurate reporting. Known for precision, fast turnaround, and exceptional client service, the company supports organizations through mergers, acquisitions, and capital market activities. Trusted by industry leaders, The Nuvo Group combines decades of experience with advanced technologies to deliver reliable, efficient solutions that meet the highest standards of accuracy and regulatory compliance.
U.S. Antimony Corporation (NYSE Texas: UAMY) is the only antimony smelter in North America, playing a critical role in securing domestic supply of this federally designated strategic and critical mineral. Antimony is an essential component for military munitions, energy storage (lithium-ion & lead-acid batteries, solar panels), semiconductors, and fire-retardant materials. In addition to antimony, the company also owns and operates Bear River Zeolite, a high-purity natural zeolite mine used in environmental remediation, agriculture, animal feed, and sustainable construction. With operations headquartered in Dallas, TX, UAMY supports U.S. supply chain independence, national defense priorities, and green technology markets.
Xtant Medical Holdings (NYSE: XTNT) is a global medical technology company focused on the design, manufacture and commercialization of regenerative biologics and spinal implant systems.
TEN Holdings, Inc. (Nasdaq: XHLD) provides event planning, production, and broadcasting services in the United States. The company organize virtual, hybrid, and physical events, including conferences, marketing events, product launches, trainings, and investors and shareholder meetings. Its events are enabled by its Xyvid Pro Platform, an internet-based broadcast platform with interactive engagement tools designed to provide web broadcast audiences with a dynamic, interactive, and engaging virtual event experience. The company also provides live streaming and video recording for physical events; video editing and production; and a custom on-demand video library for finished video content to be viewed and downloaded. It serves a range of industries, such as technology firms, healthcare organizations, educational institutions, and marketing and advertising agencies, as well as nonprofits and associations. The company was formerly known as The Events Network, Inc. and changed its name to TEN Holdings, Inc. in June 2024. The company was founded in 2011 and is based in Langhorne, Pennsylvania. TEN Holdings, Inc. is a subsidiary of V-cube, Inc.
Tudor Gold (TSX: TUD) is a precious and base metals exploration and development company with 80% interest in the Treaty Creek Project, which hosts one of the largest gold-copper-silver deposits in North America. The Treaty Creek Project has an Indicated Mineral Resource of 21.66 million oz gold, 2.87 billion pounds and 128.73 million oz silver and an Inferred Mineral Resource of 4.88 million oz gold, 503.2 million lb copper and 28.97 million oz silver. Tudor is focused on advancing the Treaty Creek Project to production.
Anixa (Nasdaq: ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.
Vizsla Royalties Corp. is a precious metals focused royalty company. The Company’s principal asset is a Net Smelter Return Royalty on Vizsla Silver Corp.’s (TSX: VZLA, NYSE: VZLA) flagship Panuco Project located in Mexico. Panuco is a world-class silver and gold development project actively advancing towards production. A Preliminary Economic Study for Panuco was published in July 2024 which highlights 15.2 Moz AgEq of annual production over an initial 10.6-year mine life, an after-tax NPV5% of US$1.1B, 86% IRR and a 9-month payback at US$26/oz Ag and US$1,975/oz Au.
eXoZymes (Nasdaq: EXOZ) has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature’s own natural processes to produce chemical compounds, enabling the company’s partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes. Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels. By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing. While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Datavault AI™ (Nasdaq: DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI's cloud-based platform offers comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable, offering AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.
Gold Royalty Corp. (NYSE American: GROY) is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. Its mission is to invest in high-quality, sustainable, and responsible mining operations to build a diversified portfolio of precious metals royalty and streaming interests that generate superior long-term returns for our shareholders.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors. In recent years, the field of cancer treatment has undergone remarkable advancement with the introduction of immunotherapy. This approach has revolutionized the landscape of cancer care. Both chemotherapy, and immunotherapy are treatment modalities that offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients. Our lead molecule LB-100 has shown remarkable synergy with chemotherapy and immunotherapy in a range of pre-clinical models.
NOUVEAU MONDE GRAPHITE (NYSE-NMG and TSX-NOU) is striving to become a key contributor to the sustainable energy revolution. The Company is working towards developing a fully integrated North American source of carbon-neutral battery anode material in Québec, Canada for the growing lithium-ion and fuel cell markets. It is fully permitted, construction ready, and has signed long-term binding and bankable offtakes with both General Motors and Panasonic Energy. With enviable ESG standards, NMG aspires to become a strategic supplier to the world’s leading battery and automotive manufacturers, providing high performing and reliable advanced materials while promoting sustainability and supply chain traceability.
Headquartered in Estero, Fl., Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract.
Focus Universal Inc. is a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G. The company had developed five disruptive patented technology platforms with 28 patents and patents pending in various phases and eight trademarks pending in various phases to solve the major problems facing hardware and software design and production within the industry today. As a process of maintenance without losing protection, the company is in the process of filing additional omnibus patents. These technologies combined to have the potential to reduce costs, product development timelines and energy usage while increasing range, speed, efficiency, and security. Focus currently trades on the Nasdaq Markets.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.
Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include its lead project, the patented KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement with the U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, ZEUS™, a solid core battery reactor, and the space focused, portable LOKI MMR™, each representing advanced developments in clean energy solutions that are modular, on-demand capable, advanced nuclear microreactors.
Founded in 2006, LogProstyle Inc. is a Japan-based real estate company that became the first unlisted Japanese company to directly list its common shares—not ADRs—on the NYSE American in March 2025. Our business spans three core segments: Real Estate Renovation & Resale, Real Estate Development, and Hotel Management. With subsidiaries established in the United States (2024) and Dubai (2025), we are expanding our footprint globally, bringing Japanese innovation and tradition to the international stage.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Global Leader in Social Commerce Software powering e-commerce in most social media platforms.
Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease for which there are limited or no treatment options. On July 26, 2024, the Company received approval by the FDA of the Company’s New Drug Application (the “NDA”) for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062 oral tablet formulation for the treatment of mild-to-moderate Alzheimer’s disease. The Company will now focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. The Company has three additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion).
High Roller Technologies, Inc. is a leading global online gaming operator known for its innovative casino brands, High Roller and Fruta, listed under the ticker ROLR on the NYSE. The Company delivers a cutting-edge real-money online casino platform that is intuitive and user-friendly. With a diverse portfolio of over 5,600 premium games from more than 90 leading game providers, High Roller Technologies serves a global customer base, offering an immersive and engaging gaming experience in the rapidly expanding multi-billion iGaming industry. The online casino features enhanced search engine optimization, machine learning, seamless direct API integrations, faster load times, and superior scalability. As an award-winning operator, High Roller Technologies continues to redefine the future of online gaming through innovation, performance, and a commitment to excellence. For more information, please visit the High Roller Technologies, Inc. investor relations website, X, Facebook, and LinkedIn pages.
NOA Lithium Brines Inc. ("NOA") is a lithium exploration and development company formed to acquire assets with significant resource potential. All NOA's projects are in the heart of the prolific Lithium Triangle, in the mining-friendly province of Salta, Argentina, near a multitude of projects and operations owned by some of the largest players in the lithium industry. NOA has rapidly consolidated a very large and impressive lithium brine claim portfolio, with key positions on three prospective salars (Rio Grande, Arizaro, Salinas Grandes) and totaling over 120,000 hectares. The Company’s recent Mineral Resource Estimate for the Rio Grande Project (July 2024) totals 4.7 million tonnes of LCE (measured, indicated and inferred) with an average lithium concentration of 525 mg/l.
51Talk Online Education Group (NYSE American: COE) is a global online education platform with core expertise in English education. The Company's mission is to make quality education accessible and affordable. The Company's online and mobile education platforms enable students to take live interactive English lessons on demand. The Company connects its students with highly qualified teachers using a shared economy approach, and employs student and teacher feedback and data analytics to deliver a personalized learning experience to its students.
Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR- powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On Perfect's direct consumer business side, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect's enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Our proprietary liposomal formulations are optimized for the delivery of agents to mucosal tissue, such as the oral cavity and the bladder lumen. Our pharmaceutical assets include a phase 2 program in oral lichen planus, and a phase 2 program in hemorrhagic cystitis.
About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit www.fractyl.com. About Revita® Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in obesity. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. In the U.S., Revita is for investigational use only under U.S. law. Revita has U.S. FDA Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP-1 drugs. A pivotal study of Revita in patients with obesity after discontinuation of GLP-1 drugs, called REMAIN-1, was initiated in the third quarter of 2024 and has completed enrollment.
Eshallgo, Inc. is a digital-first office solution provider based in Shanghai, China. The Company offers integrated hardware, printing, software, and support services to small and mid-sized businesses. In 2025, Eshallgo expanded into enterprise AI with a suite of intelligent applications that enhance document management, workflow automation, smart procurement, and secure collaboration. These tools help businesses modernize operations and boost efficiency through AI-driven insights.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer (SGX942), and Behçet's Disease (SGX945). Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg [MarVax] and Ebola [SuVax]) and coronaviruses (COVID-19; CiVax). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).
With the granting of a full mining permit in February 2025 – one of only nine such permits issued in British Columbia since 2015 – Blue Lagoon Resources has achieved a critical milestone and is now is about to start production at its High-Grade (9 g/t +) Dome Mountain Gold Mine Project. The company is poised to transition to a cash-flowing mining operation starting this November 2025. In addition to commencing mining operations on September 24, 2025, Blue Lagoon plans to use its cash flow to aggressively explore and advance the other 15 known high-grade gold veins on the property. To date, our exploration efforts have focused on just 10% of the 22,000-hectare property, leaving a vast 90% still unexplored. Our goal is to unlock the full potential of this highly prospective ground by targeting new discoveries identified during our extensive 50,000-meter drill programs conducted from 2021 to 2023.
STLLR Gold (TSX: STLR | OTCQX: STLRF ; US$110M market cap) is a Canadian gold developer with 16 million ounces in mineral resources from two large-scale gold projects, each capable of +250,000 ounces/year production profile: Tower Gold Project in Timmins, Ontario and the Colomac Gold Project in NWT. STLLR released its Tower PEA: 273,000oz annual production over 19-years, US$2.5B and 24% after-tax NPV and IRR, respectively, at US$3,200/oz gold. Our Hollinger Tailings Project, in Timmins, has the potential to be a near-term cash flow generating asset. STLLR is cashed up (US$10 million) and trades at US$6/oz enterprise value to total resources. We have a team with mine building and operating experience, with Agnico Eagle (10%) as our largest shareholder, and our goal is to advance/de-risk both projects to "shovel ready" status. Let us know if you'd like to meet.
Silver Storm Mining Ltd. holds advanced-stage silver projects located in Durango, Mexico. Silver Storm is committed to restarting operations at its 100% owned La Parrilla Silver Mine Complex, a prolific operation comprised of a 2,000 tpd mill and three underground mines. La Parrilla historically produced 34.3 million silver-equivalent ounces between 2005 and 2019. The Company also holds a 100% interest in the San Diego Project, which is among the largest undeveloped silver assets in Mexico. For more information regarding the Company and its projects, please visit our website at www.silverstorm.ca.
NanoViricides, Inc. (NYSE ticker NNVC) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. Our lead drug candidate NV-387 has completed Phase 1 trials successfully with no adverse effects and we are ready to initiate Phase 2 trials for it. NV-387 is a broad-spectrum antiviral drug has shown superiority to existing drugs in animal trials for treating RSV, COVID, Long COVID, Influenza, and MPOX/Smallpox infections. NV-387 has also shown excellent effectiveness against measles in lethal lung infection in a mouse model. The overall market size of NV-387 indications alone is estimated to be well in excess of $10 billion. In addition, MPox and Measles are orphan diseases in the USA and will be eligible for earning a PRV from the US FDA. Each PRV is currently thought to be worth $150 million to $350 million as a tradable asset. Another drug candidate is NV-HHV-1 to treat Shingles.
MySize, Inc. (NASDAQ: MYSZ) is a global leader in AI-powered size recommendation and digital commerce platforms for the fashion industry. With solutions like MySizeID and Naiz Fit, and its expansion into circular fashion through Percentil, MySize helps retailers improve fit, reduce returns, and enhance the customer journey—online and offline.
Reviva Pharmaceuticals We are a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform. We have been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries. Brilaroxazine: The Potential Future Standard of Care for Schizophrenia Our lead drug candidate, brilaroxazine, is in clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder (MDD), behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD). Our primary focus is to complete the clinical development of brilaroxazine for the treatment of acute and maintenance schizophrenia. In October 2023, we announced positive topline results and successful completion of our pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability of once-daily brilaroxazine in adults with schizophrenia. The RECOVER trial met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine compared to placebo. Importantly, we have now seen generally consistent, clinically significant efficacy and safety findings across our Phase 2 REFRESH and Phase 3 RECOVER trials further reinforcing brilaroxazine’s competitive profile. Our Commitment We are focused on advancing our pipeline of novel medicines that may have a profound impact on the lives of those affected by these medical conditions.
Silver X Mining Corp. is a rapidly expanding silver producer and developer advancing the Nueva Recuperada Project in Peru, a 20,795-hectare, district-scale land package with two mining units and over 200 targets. Current production at the Tangana Mining Unit is scaling alongside the planned restart of the Plata Mine, supporting a path to ~6 million AgEq ounces annually by 2029. With immediate revenue, scalable growth, and long-term discovery upside — all within one integrated project — Silver X is building the next-generation silver company defined by growth, resilience, and responsible mining. For more information visit our website at www.silverxmining.com.
T-REX Acquisition Corp. is a revenue stage, fully integrated crypto currency company. Through our wholly owned subsidiaries, we focus on proprietary Bitcoin mining, ownership and development of data centers, and the fabrication of mining containers used for deployment to remote mining locales.
NusaTrip is an online travel platform in Southeast Asia that has been established since 2013 and is the first online travel agent (OTA) in Indonesia to receive IATA (International Air Transport Association) accreditation and is a member of ASITA - Association of the Indonesia Tours and Travel Agencies.
Ethema Health Corporation operates in the behavioral healthcare space, specifically in the treatment of substance use disorders. By working with scientists, doctors and researchers, Ethema strives to develop better assessment and treatment modalities for the industry.
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
ZenaTech provides AI drone, Drone-as-a-Service, Quantum Computing, and SaaS-based enterprise software solutions that help businesses and government improve mission-critical operations. From drone solutions for smart farming or accessing medical supplies on the battlefield, to software applications used by law enforcement, field service technicians, and plant managers, the company’s portfolio of subsidiary brands and patented products deliver innovation, automation, and cost savings.
The brainchild of leading aerospace engineers, Aura Systems was founded in 1987 as a defense industry think-tank. During the Cold War, Aura collaborated with the nation’s largest defense contractors as well as with the military itself on a host of both classified and non-classified “Star Wars” skunkworks programs.
From infrared projection and gamma-ray surveillance to space-based missile launch, for more than thirty years, Aura’s history of technology-forward innovation has seen its technology launched into space to repair the Hubble telescope, dive to the ocean’s depths on board Los Angeles Class Nuclear Fast Attack Submarines, and soar through the air aboard F-16 reconnaissance jets. Here on land, Aura’s revolutionary AuraGen® technology has brought reliable green power to every corner of the planet.
MUSQ Global Music Industry Index ETF (NYSE: MUSQ) is the first exchange-traded fund (ETF) dedicated exclusively to the global music industry. The fund provides investors a unique opportunity to gain diversified exposure to the $100 billion music market, encompassing a wide range of industry segments, including streaming platforms, music content and distribution, live events and ticketing, and music equipment and technology. MUSQ tracks the MUSQ Global Music Industry Index, a comprehensive benchmark designed to reflect the full ecosystem of companies driving growth and innovation in the music sector.
Led by CEO David Schulhof, a seasoned music and media industry executive, MUSQ is uniquely positioned to bridge the worlds of investment and music. Schulhof’s extensive career includes leadership roles at LiveOne, AGC Studios, and IM Global Studios, as well as founding Evergreen Copyrights, where he oversaw acquisitions of iconic music catalogs. Through MUSQ, Schulhof brings a visionary approach to aligning financial opportunity with the cultural and economic power of music.
We help brands, agencies & organizations craft and deliver their stories to their ideal audience with impact and integrity
AmpliTech designs, develops, and manufactures custom leading-edge RF components for the Commercial, SATCOM, Space, and Military markets. These designs cover frequencies from 50 kHz to 44 GHz. AmpliTech also has developed new products for the 5G/6G wireless ecosystem and infrastructure with unparalleled performance. In addition to this rapidly emerging market, AMPG has also developed solutions for Quantum Computing, with cutting edge technology. We continue to blaze trails in our commitment to enable and accelerate the arrival of true 5G/6G architecture and contribute to the U.S. being the leader and first to reach the coveted position of Quantum Supremacy.
PetVivo Holdings, Inc. (OTCQX: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals.
Commitment to diversity is a core value at Kaufman & Canoles, and it is our mission to maintain equality throughout all aspects of our business. Not only does it make us a stronger, better service provider for our clients, it is simply the right thing to do.
At CORE IR, we offer incomparable relationship introductions with institutional investors, retail broker-dealers, fund managers, family offices, investment bankers, and analysts.
We craft compelling messages that resonate with current and prospective investors. We leverage advanced tools to measure, benchmark, and elevate the ROI of your IR program.
Our comprehensive communications and digital media plans allow us to seamlessly integrate with key constituents to unify all communications.
